Key result
Stereotactic arrhythmia radioablation eliminates recurrent VT and reduces daily PVCs in refractory ischemic disease.
Why the study?
To demonstrate the first clinical experience of stereotactic arrhythmia radioablation (STAR) for antiarrhythmic drug (AAD) refractory ventricular tachycardia (VT) in Russia.
Does stereotactic arrhythmia radioablation reduce ventricular tachycardia episodes in patients with refractory ischemic VT?
Case Report (n=1)
No
Does stereotactic arrhythmia radioablation reduce ventricular tachycardia episodes in patients with refractory ischemic VT?
Answers are grounded in this paper and cite their sources.
Stereotactic radioablation is a feasible and potentially highly effective non-invasive alternative for treating ventricular tachycardia refractory to drugs and catheter ablation.
The aim of the study is the demonstration of the 1 st clinical experience of stereotactic arrhythmia radioablation (STAR) of the patient with antiarrhythmic drug (AAD) refractory ventricular tachycardia (VT) in Russia. The results of STAR of 57 years old patient with AAD and multiple radiofrequency ablation refractory VT are described. This clinical study demonstrates efficacy and safety of STAR of VT.
No takes yet. Share an insight, caveat, or question.
Ревишвили et al. (2022) conducted a case report in Refractory ventricular tachycardia (n=1). Stereotactic arrhythmia radioablation was evaluated on Reduction in ventricular tachycardia episodes and PVCs. Stereotactic arrhythmia radioablation eliminated ventricular tachycardia paroxysms by 62-90 days post-procedure and reduced daily PVCs without early complications in a patient with refractory ischemic VT.
Synapse has enriched 10 related papers. Consider them for comparative context: